Clover Biopharmaceuticals, Ltd. (2197.HK)
Clover Biopharmaceuticals, Ltd.
No. 758 West Nanjing Road
Room 1901 Jing'an District
Shanghai
China
https://www.cloverbiopharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 387
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Peng Liang Ph.D. | Founder, Chief Scientific Officer & Chairman of the Board | 3.08M | N/D | 1961 |
| Mr. Joshua G. Liang | CEO & Executive Director | 4.82M | N/D | 1993 |
| Dr. Yang Li Ph.D. | Chief Technology Officer | N/D | N/D | N/D |
| Ms. Htay Htay Han MBBS | Chief Medical Officer of Vaccine | N/D | N/D | 1969 |
| Dr. Berry Michael Ph.D. | Chief Technical Operation Officer | N/D | N/D | 1966 |
| Ms. Abigail Bracha Ph.D. | Senior Vice President of Corporate Strategy & Business Development | N/D | N/D | N/D |
| Ms. Tracy Wang | Senior Vice President of Head of Regulatory Affairs, China | N/D | N/D | N/D |
| Dr. Nicholas Jackson M.Sc., Ph.D. | President of Global Research & Development | N/D | N/D | 1971 |
| Mr. LiongHo Chua | President of Greater China | N/D | N/D | 1964 |
| Dr. Igor Smolenov M.D., Ph.D. | Executive Vice President of Global Clinical Development Vaccines | N/D | N/D | N/D |
Descripción
Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China. Its product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine; AdimFlu-S (QIS), a quadrivalent split inactivated vaccine for the treatment of influenza A and B; SCB-219M, a thrombopoietin receptor agonist mimetic bispecific Fc-fusion protein to treat cancer patients with chemotherapy-induced thrombocytopenia; and SCB-313, an oncology product candidate for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis. The company is also developing SCB-2023B for COVID-19 treatment; SCB-1019, a product development platform for the creation of protein-based vaccines based on naturally trimerization-dependent targets; and SCB-1001 for rabies treatment. In addition, it provides consulting services and sells biopharmaceutical drugs. The company was founded in 2007 and is headquartered in Shanghai, the People's Republic of China.
Gestión corporativa
La calificación ISS Governance QuickScore de Clover Biopharmaceuticals, Ltd. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
